Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 344

Similar articles for PubMed (Select 18548994)

1.

Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.

Khouri S, Kotliroff A, Lishner M, Amital H.

Isr Med Assoc J. 2008 Apr;10(4):320-1. No abstract available.

2.

[Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].

Martínez Pascual C, Valdés Mas M, de la Peña Moral JM, Miras López M.

Med Clin (Barc). 2011 Sep 17;137(7):329-30. doi: 10.1016/j.medcli.2010.09.011. Epub 2010 Nov 11. Spanish. No abstract available.

PMID:
21074222
3.

Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.

Tamura T, Tasaka T, Fujimoto M, Matsuhashi Y, Fukumot T, Mano S, Kuwajima M, Nagai M.

Haematologica. 2004 Sep;89(9):ECR32. No abstract available.

4.

[Adverse effects of imatinib mesylate].

Isshiki I.

Nihon Rinsho. 2007 Jan 28;65 Suppl 1:404-7. Review. Japanese. No abstract available.

PMID:
17474438
5.
6.

Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.

Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S.

J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8. doi: 03.2008/JCPSP.176178.

PMID:
18460249
7.

Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.

Al-Kali A, Farooq S, Tfayli A.

J Clin Pharm Ther. 2009 Oct;34(5):607-10. doi: 10.1111/j.1365-2710.2009.01035.x.

PMID:
19744017
8.

Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.

Thierry A, Dreyfus B, Bridoux F, Abou Ayache R, Milin S, Guilhot F, Touchard G.

Nephrol Dial Transplant. 2007 Jun;22(6):1791-2. Epub 2007 Feb 17. No abstract available.

9.

Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.

Papaioannou G, Athanasiadou A, Voutiadou G, Gaitatzi M, Batsis I, Touloumenidou T, Anagnostopoulos A.

Cancer Genet. 2011 Dec;204(12):692-3. doi: 10.1016/j.cancergen.2011.11.004. No abstract available.

PMID:
22285023
10.

[Severe imatinib-induced hepatotoxicity].

García Hernández FJ, González León R, Castillo Palma MJ, Sánchez Román J.

Med Clin (Barc). 2012 May 19;138(14):638; author reply 638-9. doi: 10.1016/j.medcli.2011.09.034. Epub 2011 Dec 3. Spanish. No abstract available.

PMID:
22137996
11.

Imatinib mesylate (gleevec) hepatotoxicity.

Mindikoglu AL, Regev A, Bejarano PA, Martinez EJ, Jeffers LJ, Schiff ER.

Dig Dis Sci. 2007 Feb;52(2):598-601. Epub 2007 Jan 12. No abstract available.

PMID:
17219077
12.

Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.

Woo SM, Huh CH, Park KC, Youn SW.

J Dermatol. 2007 Oct;34(10):724-6. No abstract available.

PMID:
17908148
13.

Imatinib: a designer drug, another cutaneous complication.

Dickens E, Lewis F, Bienz N.

Clin Exp Dermatol. 2009 Jul;34(5):603-4. doi: 10.1111/j.1365-2230.2009.03250.x. Epub 2009 May 26.

PMID:
19486036
14.

Peripheral neuropathy as an adverse effect of imatinib therapy.

Chakupurakal G, Etti RJ, Murray JA.

J Clin Pathol. 2011 May;64(5):456. doi: 10.1136/jcp.2010.085936. Epub 2011 Jan 28. No abstract available.

PMID:
21278395
15.

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.

Park SJ, Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS.

Acta Haematol. 2007;118(4):219-21. Epub 2007 Nov 29. No abstract available.

PMID:
18057867
16.

Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.

Michael M, Antoniades M, Lemesiou E, Papaminas N, Melanthiou F.

Oncologist. 2009 Dec;14(12):1198-200. doi: 10.1634/theoncologist.2009-0165. Epub 2009 Dec 2.

17.

Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.

Busuttil DP.

Int J Lab Hematol. 2008 Feb;30(1):68-70. doi: 10.1111/j.1751-553X.2006.00863.x.

PMID:
18190471
18.

Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.

Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY, Cho MS, Mun YC, Nam E, Lee SN, Seong CM.

Acta Haematol. 2007;118(4):205-8. Epub 2007 Nov 15.

PMID:
18030002
19.

Dermatological toxicity of imatinib mesylate.

Prasad N, Deshmukh C, Biswas G, Bakshi A, Sastry PS, Parikh PM.

J Assoc Physicians India. 2005 Apr;53:298. No abstract available.

PMID:
15987015
20.

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.

François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P.

Am J Kidney Dis. 2008 Feb;51(2):298-301. doi: 10.1053/j.ajkd.2007.10.039.

PMID:
18215707
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk